Key result
Simvastatin 40 mg daily for 6 months significantly improved myocardial perfusion abnormalities in patients with slow coronary flow, whose baseline TIMI frame count correlated with reversibility score (r=0.84, p=0.0001).
Why the study?
Does simvastatin improve myocardial perfusion abnormality in patients with slow coronary flow?
Does simvastatin improve myocardial perfusion abnormality in patients with slow coronary flow?
Simvastatin 40 mg daily for 6 months improves myocardial perfusion abnormalities in patients with slow coronary flow.
May support simvastatin evaluation in slow coronary flow; leaves open randomized confirmation before practice change.
BACKGROUND: The slow coronary flow (SCF) phenomenon is a coronary microvascular disorder characterized by the delayed passage of contrast in the absence of obstructive epicardial coronary disease. Recent studies showed the possible role of endothelial dysfunction, diffuse atherosclerosis and inflammation in the pathogenesis of this phenomenon. We aimed to investigate the effect of statin on myocardial perfusion in patients with SCF. METHODS AND RESULTS: The study population consisted of 97 patients with SCF. Coronary flow patterns of the cases are determined by thrombolysis in myocardial infarction (TIMI) frame count method. Single-photon emission computed tomographic myocardial perfusion imaging studies and lipid parameters of the patients were obtained before and after 6 months of simvastatin treatment period. During the study, daily single dose of 40 mg simvastatin has been given to each subject. We found a significant positive correlation between mean TIMI frame count and basal reversibility score (r = 0.84, p = 0.0001). In addition, analysis of the reversibility scores demonstrates that simvastatin treatment has significantly improved the myocardial perfusion abnormality at the end of the follow-up period. CONCLUSION: Present findings allow us to conclude that simvastatin improved myocardial perfusion in patients with SCF.
No takes yet. Share an insight, caveat, or question.
Çakmak et al. (2007) studied Slow coronary flow (SCF) (n=97). Simvastatin was evaluated on Myocardial perfusion abnormality (reversibility score). Simvastatin 40 mg daily for 6 months significantly improved myocardial perfusion abnormalities in patients with slow coronary flow, whose baseline TIMI frame count correlated with reversibility score (r=0.84, p=0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: